Publicacións nas que colabora con Carlos Panizo Santos (8)

2022

  1. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study

    Haematologica, Vol. 107, Núm. 11, pp. 2675-2684

2020

  1. RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group

    Annals of Hematology, Vol. 99, Núm. 4, pp. 799-808

2017

  1. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

    Blood

2015

  1. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: Results of the PRO-R-IPI study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, Núm. 7, pp. 398-403

2014

  1. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: Results of a prospective, multicenter, phase II clinical trial

    Haematologica

  2. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: Results of a prospective, multicenter, phase II clinical trial

    Haematologica, Vol. 99, Núm. 3, pp. 505-510

  3. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

    The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111

2010

  1. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era

    European Journal of Haematology, Vol. 85, Núm. 4, pp. 321-328